IP Library › Granted Patent US 12,502,369
Granted Patent B2
US 12,502,369 · App. 15/765,124 · Granted Dec 23, 2025

Methods of cancer treatment

Inventors: Ruihong Chen (Burlingame, CA); Chun Jiang (Hillsborough, CA)
A61K31/215A61K31/122A61K31/336A61K31/35G01N33/5011G01N2333/912
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,502,369
App. No.
15/765,124
Granted
Dec 23, 2025
Kind
B2
Abstract

This present disclosure is directed to a method of selecting a cancer for treatment with protein kinase C (PKC) activators, and corresponding methods of treating the cancer with PKC activators.

Claims (48)

1 . A method of treating a patient with cancer, comprising: treating cancer cells of a patient with a diterpenoid protein kinase C (PKC) activator, determining phosphorylation status of one or more human PKC proteins, identifying the cancer having cancer cells that have increased phosphorylation of the one or more human PKC proteins following treatment with the diterpenoid PKC activator, and administering to the patient with the identified cancer a therapeutically effective amount of the diterpenoid PKC activator, wherein the one or more of human PKC proteins is selected from the group consisting of PKCδ, PKCε, PKCη, PKCθ and PKCμ and the cancer is selected from the group consisting of bladder cancer, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, gastric cancer, head and neck cancer, leukemia, liver cancer, non-small cell lung cancer, lymphoma, skin cancer, melanoma, myeloma, ovarian cancer, pancreatic cancer, prostate cancer, and renal cancer, and wherein the diterpenoid PKC activator is a compound of structural formula (III):

or an enantiomer, hydrate, solvate, or pharmaceutically acceptable salt thereof,

wherein

R 3 is O, S or N double bonded to the ring carbon, or R 3 is-OR a , wherein R a is H, an optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted alkylcarbonyl, optionally substituted alkenylcarbonyl, optionally substituted cycloalkylcarbonyl, optionally substituted arylcarbonyl, optionally substituted heteroarylcarbonyl, optionally substituted arylalkylcarbonyl, optionally substituted heteroarylalkylcarbonyl, arylalkenylcarbonyl, optionally substituted heteroarylalkenylcarbonyl;

R 4 and R 5 are independently H, halo, cyano, or R 4 is —OR c , wherein R c is H, an optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted alkylcarbonyl, optionally substituted alkenylcarbonyl, optionally substituted cycloalkylcarbonyl, optionally substituted arylcarbonyl, optionally substituted heteroarylcarbonyl, optionally substituted arylalkylcarbonyl, optionally substituted arylalkenylcarbonyl, optionally substituted heteroarylalkylcarbonyl, optionally substituted heteroarylalkenylcarbonyl;

R 5 ′ and R 6 ′ are H, or R 5 ′ and R 6 ′ together form a bond or are bonded to a common oxygen atom to form an epoxide;

R 6 ′ and R 7 ′ are H, or R 6 ′ and R 7 ′ together form a bond or are bonded to a common oxygen atom to form an epoxide;

R 9 is H or -OR f , wherein R f is H, an optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkylcarbonyl; optionally substituted arylcarbonyl, optionally substituted heteroarylcarbonyl, optionally substituted arylalkylcarbonyl, optionally substituted heteroarylalkylcarbonyl, or optionally substituted arylalkyloxycarbonyl;

R 13 is H, halo, carbamate, phosphine, phosphoramide, phosphoramidite, phosphoramidate, phosphonate, sulfonamide, amide, guanidine, urea, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or -OR h , wherein R h is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted alkylcarbonyl, optionally substituted alkenylcarbonyl, optionally substituted alkynylcarbonyl, optionally substituted arylcarbonyl, optionally substituted heteroarylcarbonyl, optionally substituted arylalkylcarbonyl, optionally substituted arylalkenylcarbonyl, optionally substituted heteroarylalkylcarbonyl, optionally substituted heteroarylalkenylcarbonyl;

R 16 is H, halo, or -O-R d , wherein R d is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted arylalkenyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted alkylcarbonyl, optionally substituted alkenylcarbonyl, optionally substituted alkynylcarbonyl, optionally substituted arylcarbonyl, optionally substituted heteroarylcarbonyl, optionally substituted arylalkylcarbonyl, optionally substituted arylalkenylcarbonyl, optionally substituted heteroarylalkylcarbonyl, optionally substituted heteroarylalkenylcarbonyl, optionally substituted carboxyalkylcarbonyl, optionally substituted amino acid carbonyl, or R d is a promoiety which is hydrolyzable under biological conditions to yield an -OH group—at the C20 carbon atom; and

R 17 and R 18 are each independently H, OH, amino, thiol, sulfanyl, sulfinyl, sulfonyl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyloxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted cycloalkyloxy, optionally substituted cycloalkenyloxy, optionally substituted heterocycloalkyloxy, optionally substituted aryloxy, optionally substituted heteroaryloxy, optionally substituted arylalkyloxy, optionally substituted arylalkenyloxy, optionally substituted heteroarylalkyloxy, optionally substituted heteroarylalkenyloxy, optionally substituted alkylcarbonyloxy, optionally substituted alkenylcarbonyloxy, optionally substituted alkynylcarbonyloxy, optionally substituted arylcarbonyloxy, optionally substituted heteroarylcarbonyloxy, optionally substituted arylalkylcarbonyloxy, optionally substituted arylalkenylcarbonyloxy, optionally substituted heteroarylalkylcarbonyloxy, optionally substituted heteroarylalkenylcarbonyloxy, optionally substituted carboxyalkylcarbonyloxy, optionally substituted amino acid carbonyloxy, phosphine, phosphate, phosphoramide, phosphoramidite, phosphoramidate, phosphonate, sulfate, sulfonate, sulfonamide, sulfone, sulfite, amide, guanidine, urea, or a progroup which is hydrolyzable under biological conditions to yield an -alkyl-OH group.

2 . The method of claim 1 , wherein the cancer is selected for treatment based on phosphorylation status of PKCδ or PKCμ.

3 . The method of claim 2 , wherein the one or more human PKC proteins is PKCμ, wherein the increased phosphorylation is at amino acid position Ser910, and wherein the cancer identified as having an increase in phosphorylation at amino acid position Ser910 in presence of the diterpenoid PKC activator is selected for treatment.

4 . The method of claim 2 , wherein the cancer is selected for treatment based on phosphorylation status of PKCμ at amino acid position Ser738 and/or Ser742, wherein the cancer identified as having an increase in phosphorylation at amino acid position Ser738 and/or Ser742 in presence of the diterpenoid PKC activator is selected for treatment.

5 . The method of claim 2 , wherein the cancer is selected for treatment based on phosphorylation status of PKCδ at amino acid position Thr507, wherein the cancer identified as having an increase in phosphorylation at amino acid position Thr507 in presence of the diterpenoid PKC activator is selected for treatment.

6 . The method of claim 1 , wherein the cancer selected for treatment is further identified as having an oncogenic or activating K-ras and/or N-ras mutation.

7 . The method of claim 1 , wherein the PKC activator comprises a compound of formula (IIIa) or (IIIb):

or an enantiomer, hydrate, solvate, or pharmaceutically acceptable salt thereof,

wherein

R 3 ; R 4 , R 5 , R 5 ′, R 6 ′, R 7 ′, R 9 , R 13 , and R 16 are as defined for formula (III);

R 17 or R 18 is H, OH, amino, thiol, sulfanyl, sulfinyl, sulfonyl, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyloxy, optionally substituted aryloxy, optionally substituted arylalkyloxy, phosphine, phosphate, phosphoramide, phosphoramidite, phosphoramidate, phosphonate, sulfate, sulfonate, sulfonamide, sulfone, sulfite, amide, guanidine, or urea; and

R 17 ′ or R 18 ′ is H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted arylalkenyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted alkylcarbonyl, optionally substituted alkenylcarbonyl, optionally substituted alkynylcarbonyl, optionally substituted arylcarbonyl, optionally substituted heteroarylcarbonyl, optionally substituted arylalkylcarbonyl, optionally substituted arylalkenylcarbonyl, optionally substituted heteroarylalkylcarbonyl, optionally substituted heteroarylalkenylcarbonyl, optionally substituted carboxyalkylcarbonyl, optionally substituted amino acid carbonyl, or a progroup which is hydrolyzable under biological conditions to yield an -OH group.

8 . The method of claim 1 , wherein the PKC activator comprises a compound of formula (IIIc):

or an enantiomer, hydrate, solvate, or pharmaceutically acceptable salt thereof,

wherein,

R 18 ′ is H, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heteroalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted arylalkenyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted alkylcarbonyl, optionally substituted alkenylcarbonyl, optionally substituted alkynylcarbonyl, optionally substituted arylcarbonyl, optionally substituted heteroarylcarbonyl, optionally substituted arylalkylcarbonyl, optionally substituted arylalkenylcarbonyl, optionally substituted heteroarylalkylcarbonyl, optionally substituted heteroarylalkenylcarbonyl, optionally substituted carboxyalkylcarbonyl, optionally substituted amino acid carbonyl, or a promoiety which is hydrolyzable under biological conditions to yield an -OH group;

R 31 , R 32 , and R 33 are each independently H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted alkylcarbonyl, optionally substituted alkenylcarbonyl, optionally substituted alkynylcarbonyl, optionally substituted arylcarbonyl, optionally substituted heteroarylcarbonyl, optionally substituted arylalkylcarbonyl, optionally substituted arylalkenylcarbonyl, optionally substituted heteroarylalkylcarbonyl, optionally substituted heteroarylalkenylcarbonyl; and

R 34 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted arylalkenyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted alkylcarbonyl, optionally substituted alkenylcarbonyl, optionally substituted alkynylcarbonyl, optionally substituted arylcarbonyl, optionally substituted heteroarylcarbonyl, optionally substituted arylalkylcarbonyl, optionally substituted arylalkenylcarbonyl, optionally substituted heteroarylalkylcarbonyl, optionally substituted heteroarylalkenylcarbonyl, optionally substituted carboxyalkylcarbonyl, optionally substituted amino acid carbonyl, or R 34 is a promoiety which is hydrolyzable under biological conditions to yield an -OH group—at the C20 carbon atom.

9 . The method of claim 1 , wherein the PKC activator comprises a compound of formula (IIId):

or an enantiomer, hydrate, solvate, or pharmaceutically acceptable salt thereof,

wherein

R 31 , R 32 , and R 33 are each independently H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl, optionally substituted alkylcarbonyl, optionally substituted alkenylcarbonyl, optionally substituted alkynylcarbonyl, optionally substituted arylcarbonyl, optionally substituted heteroarylcarbonyl, optionally substituted arylalkylcarbonyl, optionally substituted arylalkenylcarbonyl, optionally substituted heteroarylalkylcarbonyl, optionally substituted heteroarylalkenylcarbonyl; and

R 34 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, optionally substituted arylalkenyl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted alkylcarbonyl, optionally substituted alkenylcarbonyl, optionally substituted alkynylcarbonyl, optionally substituted arylcarbonyl, optionally substituted heteroarylcarbonyl, optionally substituted arylalkylcarbonyl, optionally substituted arylalkenylcarbonyl, optionally substituted heteroarylalkylcarbonyl, optionally substituted heteroarylalkenylcarbonyl, optionally substituted carboxyalkylcarbonyl, optionally substituted amino acid carbonyl, or R 34 is a promoiety which is hydrolyzable under biological conditions to yield an -OH group—at the C20 carbon atom.

10 . The method of claim 1 , the PKC activator comprises a compound of formula (IIIe):

or an enantiomer, hydrate, solvate, or pharmaceutically acceptable salt thereof,

wherein,

R 31 , R 32 , R 33 , and R 34 are as defined for formula (IIIc).

11 . The method of claim 1 , wherein the cancer is bladder cancer, breast cancer, cervical cancer, colorectal cancer, esophageal cancer, gastric cancer, head and neck cancer, liver cancer, non-small cell lung cancer, skin cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, or renal cancer.

12 . The method of claim 1 , wherein the cancer is pancreatic cancer.

13 . The method of claim 1 , wherein the cancer is breast cancer.

14 . The method of claim 1 , wherein the cancer is colorectal cancer.

15 . The method of claim 1 , wherein the cancer is non-small cell lung cancer.

16 . The method of claim 1 , wherein the cancer is prostate cancer.

17 . The method of claim 1 , wherein the cancer is head and neck cancer.

18 . The method of claim 1 , wherein the cancer is skin cancer.

19 . The method of claim 1 , wherein the cancer is melanoma.

20 . The method of claim 1 , wherein the cancer is leukemia, lymphoma, or myeloma.

21 . The method of claim 1 , wherein the treatment of the cancer with the compound of formula (III) is conducted on a biological sample of the cancer obtained from the patient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2023
From: CHEN, RUIHONG; JIANG, CHUN
To: K-GEN THERAPEUTICS, INC.
Reel/Frame 063224/0126 →
Continuity (3)
Provisional Application 62306019 · Mar 9, 2016
Provisional Application 62253701 · Nov 11, 2015
Related Publication 20180271819A1 · Sep 27, 2018
References Cited (97)
US 4716179A · Hecker · 1987 [cited by applicant]
US 5145842A · Driedger · 1992 [cited by applicant]
US 6268395B1 · Hattori · 2001 [cited by applicant]
US 6432452B1 · Aylward · 2002 [cited by applicant]
US 8022103B2 · Xu · 2011 [cited by applicant]
US 8067632B2 · Wender · 2011 [cited by applicant]
US 8106092B2 · Ogbourne · 2012 [cited by applicant]
US 8431612B2 · Xu · 2013 [cited by applicant]
US 8536378B2 · Wender · 2013 [cited by applicant]
US 8816122B2 · Wender · 2014 [cited by applicant]
US 8901356B2 · Hogburg · 2014 [cited by applicant]
US 9102687B2 · Grue-SøRensen · 2015 [cited by applicant]
US 9314458B2 · Aylward · 2016 [cited by applicant]
US 10099996B2 · Han · 2018 [cited by applicant]
US 10278934B2 · Han · 2019 [cited by applicant]
US 20080069809A1 · Ogbourne · 2008 [cited by applicant]
US 20090187046A1 · Wender · 2009 [cited by applicant]
US 20100204318A1 · Obgourne · 2010 [cited by applicant]
US 20110014699A1 · Wender · 2011 [cited by applicant]
US 20120101283A1 · Wender · 2012 [cited by applicant]
US 20130324600A1 · Grue-Sørensen · 2013 [cited by applicant]
US 20130331446A1 · Grue-Sørensen · 2013 [cited by applicant]
US 20140018329A1 · Han · 2014 [cited by examiner]
US 20140371311A1 · Oh · 2014 [cited by applicant]
US 20150175622A1 · Laing · 2015 [cited by applicant]
WO 2013182688A1 · 2013 [cited by applicant]
WO 2014066967A1 · 2014 [cited by applicant]
Ersvaer et al (Toxins, 2010; 2:174-194) (Year: 2010). [cited by examiner]
Smanski et al (Methods in Enzymology, 2012; 515:163-186) (Year: 2012). [cited by examiner]
Gura et al (Science, 1997, 278:1041-1042); (Year: 1997). [cited by examiner]
Johnson et al (British Journal of Cancer, 2001, 84:1424-1431); and (Year: 2001). [cited by examiner]
Mochly-Rosen et al (Nat Rev Drug Discov, 2012; 11:937-957) (Year: 2012). [cited by examiner]
Ochi et al (J Cell Physiol, 2011; 226:1074-1081) (Year: 2011). [cited by examiner]
Azmi (Future Med Chem, 2012; 4(8),939-941) (Year: 2012). [cited by examiner]
Dawson (Science, 2017; 355:1147-1152) (Year: 2017). [cited by examiner]
Hunger-Glaser (JBC, 2003; 278(25):22631-22643) (Year: 2003). [cited by examiner]
Brändlin et al (JBC, 2002; 277(8):6490-6496) (Year: 2002). [cited by examiner]
Ali, et al., “Protein kinases C isozymes are differentially expressed in human breast carcinomas,” Life Sci. 2009; 84(21-22):766-771. [cited by applicant]
Antal et al., “Cancer-Associated Protein Kinase C Mutations Reveal Kinase's Role as Tumor Suppressor,” Cell, 2015; 160:489-502. [cited by applicant]
Barcelo et al., “Phosphorylation at Ser-181 of Oncogenic KRAS Is Required for Tumor Growth,” Cancer Res., 2014; 74(4):1190-1199. [cited by applicant]
Basu “The Potential of Protein Kinase C as a Target for Anticancer Treatment,” Pharmac Ther., 1993; 59(3):257-280. Entire Document. [cited by applicant]
Beans et al., “Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo,” Proc Natl Acad Sci USA., 2013; 110(29):11698-11703. [cited by applicant]
Bentley et al., “Accurate Whole Human Genome Sequencing using Reversible Terminator Chemistry,” Nature, 2008; 456(7218): 53-59. [cited by applicant]
Bond et al., “Cytotoxic Action of Phorbol Esters on Human Pancreatic Cancer CellsInt J Cancer.,” 2007; 121(7):1445-54. [cited by applicant]
Cariello et al., “Resolution of a missense mutant in human genomic DNA by denaturing gradient gel electrophoresis and direct sequencing using in vitro DNA amplification: HPRT Munich,” Am J Hum Genet., 1988; 42(5):726-73… [cited by applicant]
Chen et al., “Absolute quantitation of endogenous proteins with precision and accuracy using a capillary Western system,” Anal Biochem., 2013; 442(1):97-103 [cited by applicant]
Chen et al., “An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate,” JAMA Intern Med., 2019; 179(7):915-921. [cited by applicant]
Chin et al., “Nonhybrid, finished microbial genome assemblies from long-read SMRT sequencing data,” Nat Methods, 2013; 10(6):563-569. [cited by applicant]
Clark, et al., “Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance,” Cancer Res., 2003; 63(4):780-786. [cited by applicant]
Cotton et al., “Reactivity of cytosine and thymine in single-base-pair mismatches with hydroxylamine and osmium tetroxide and its application to the study of mutations,” Proc Natl Acad Sci USA., 1988; 85(12):4397-4401. [cited by applicant]
Drmanac et al., “Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays,” Science, 2010; 327(5961):78-81. [cited by applicant]
Elisabah et al., “Immunohistochemical assay for detection of K-ras protein expression in metastatic colorectal cancer,” 2013; J Egypt Natl Cancer Inst 25(1):51-56. [cited by applicant]
Ersvaer et al., “The Protein Kinase C Agonist PEP005 (Ingenol 3-Angelate) in the Treatment of Human Cancer: A Balance between Efficacy and Toxicity,” Toxins, 2010; 2:174-194, abstract; p. 178, para 4 to p. 179, Para 1; … [cited by applicant]
Garczarczyk et al., “Protein kinase Cγ in colon cancer cells: Expression, Thr [cited by applicant]
Genbank Database [Online] (Oct. 17, 2008) “ [cited by applicant]
Genbank Database [Online] (Dec. 29, 2018) “GTPase Nras [ [cited by applicant]
Genbank Database [Online] (Oct. 23, 2008) “Human N-ras Mrna and flanking regions,” Accession No. X02751.1 Accessible on the Internet at URL: http://www.ncbi.nlm.nih.gov/nuccore/X02751. [cited by applicant]
Hamilton et al., “Constitutive Association of c-N-Ras with c-Raf-1 and Protein Kinase Cε in Latent Signaling Modules,” J Biol Chem., 2001; 276(31):29079-29090. [cited by applicant]
Han, et al., “Expression and function of classical protein kinase C isoenzymes in gastric cancer cell line and its drug-resistant sublines,” World J Gastroenterol., 2002; 8(3):441-445. [cited by applicant]
Iori et al., “In situ protein Kinase C activity is increased in cultured fibroblasts from Type 1 diabetic patients with nephropathy,” Diabetolgia, 2003; 46(4):524-530. [cited by applicant]
Igumenova, “Dynamics and membrane interactions of protein kinase C,” Biochemistry, 2015; 54(32):4953-4968. [cited by applicant]
Jarvius et al., “In Situ Detection of Phosphorylated Platelet-derived Growth Factor Receptor β Using a Generalized Proximity Ligation Method,” 2007; Method Mol Cell Proteomics 6(9):1500-1509. [cited by applicant]
Kawamura et al., “Nineteen-step total synthesis of (+)-phorbol,” Nature, 2016; 532:90-93. [cited by applicant]
Karabacak et al., “Microfluidic, marker-free isolation of circulating tumor cells from blood samples,” Nat Protoc., 2014; 9(3):694-710. [cited by applicant]
Kazanietz et al., “Residues in the Second Cysteine-rich Region of Protein Kinase C δ Relevant to Phorbol Ester Binding as Revealed by Site-directed Mutagenesis,” J Biol Chem., 1995; 270(37):21852-21859. [cited by applicant]
Kornev et al., “Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism,” Proc Natl Acad Sci USA., 2006; 103(47): 17783-17788. [cited by applicant]
Lu et al., “Tumor Promotion by Depleting Cells of Protein Kinase Cδ,” Mol Cell Biol., 1997; 17(6):3418-3428. [cited by applicant]
Manzow, et al., “Evidence against a role of general protein kinase C downregulation in skin tumor promotion,” Int J Cancer., 2000; 85(4): 503-507. [cited by applicant]
Marguiles et al., “Genome sequencing in microfabricated high-density picolitre reactors,” Nature, 2005; 437(7057):376-380. [cited by applicant]
Mullin et al., “Increased Tight Junction Permeability Can Result from Protein Kinase C Activation/Translocation and Act as a Tumor Promotional Event in Epithelial Cancers,” Adv Drug Deliv Rev; Annals of the New York Aca… [cited by applicant]
Newton, “Protein kinase C: poised to signal,” Am J Physiol Endocrinol Metab., 2010; 298:E395-E402. [cited by applicant]
Nishikawa et al., “Determination of the Specific Substrate Sequence Motifs of Protein Kinase C Isozymes,” J Biol Chem., 1997; 272(2):952-960. [cited by applicant]
Niu et al., “In vitro human cell line models to predict clinical response to anticancer drugs,” Pharmacogenomics., 2015; 16(3):273-285. [cited by applicant]
Picato—Highlights of Prescribing Information, Revised 2017 (11 pages). [cited by applicant]
Shenk et al., “Biochemical method for mapping mutational alterations in DNA with S1 nuclease: the location of deletions and temperature-sensitive mutations in simian virus 40,” Proc Natl Acad Sci USA., 1975; 72(3):989-9… [cited by applicant]
Steinberg, “Structural Basis of Protein Kinase C Isoform Function,” Physiol Rev., 2008; 88(4): 1341-1378. [cited by applicant]
Stott et al., “Isolation of circulating tumor cells using a microvortex-generating herringbone-chip,” Proc Natl Acad Sci USA., 2010; 107(43):18392-18397. [cited by applicant]
Toomik et al., “A potent and highly selective peptide substrate for protein kinase C assay,” Biochem J., 1997; 322(2):455-460. [cited by applicant]
Tsai et al., “Isolation of Phorbol Esters from Euphorbia grandicornis and Evaluation of Protein Kinase C- and Human Platelet-Activating Effects of Euphorbiacease Diterpenes,” J Nat Prod., 2016; 79(10):2658-2666. [cited by applicant]
Van de Stolpe et al., “Circulating tumor cell isolation and diagnostics: toward routine clinical use,” Cancer Res., 2011; 71(18):5955-5960. [cited by applicant]
Vila-Petroff et al., “Ca [cited by applicant]
Wang et al., “Role of Hydrophobic Residues in the C1b Domain of Protein Kinase C δ on Ligand and Phospholipid Interactions,” J Biol Chem., 2001; 276(22):19580-19587. [cited by applicant]
Wang et al., “Substrate Recognition Mechanism of Atypical Protein Kinase Cs Revealed by the Structure of PKCt in Complex with a Substrate Peptide from Par-3,” Structure, 2012; 20(6):791-801. [cited by applicant]
Wang et al., “K-Ras Promotes Tumorigenicity Through Suppression of Non-canonical Wnt Signaling,” Cell, 2015; 163:1237-1251. [cited by applicant]
Wender et al., “Practical Synthesis of Prostratin, DPP, and Their Analogs, Adjuvant Leads Against Latent HIV,” Science, 2008; 320(5876):649-652. [cited by applicant]
Wender et al., “A Gateway Synthesis, PKC Affinities and Cell Growth Activities of Daphnane Congeners,” Nat Chem., 2011; 3(8):615-619. [cited by applicant]
Winter et al., “A method to detect and characterize point mutations in transcribed genes: amplification and overexpression of the mutant c-Ki-ras allele in human tumor cells,” Proc Natl Acad Sci USA., 1985; 82(22):7575-… [cited by applicant]
Yin et al., “Tumor-Initiating Cells and FZD8 Play a Major Role in Drug Resistance in Triple-Negative Breast Cancer,” Mol Cancer Ther., 2013; 2013 12(4):491-498. [cited by applicant]
Yoshida et al., “Antitumor activity of daphnane-type diterpene gnidimacrin isolated from Stellera chamaejasme L” Int J Cancer, 1996; 66(2):268-273. [cited by applicant]
Yu, et al., “Circulating tumor cells: approaches to isolation and characterization,” J Cell Biol., 2011; 192(3):373-382. [cited by applicant]
Zhang et al., “Phosphoprotein analysis using antibodies broadly reactive against phosphorylated motifs,” J Biol Chem., 2002; 277(42):39379-39387. [cited by applicant]
Zheng et al., “Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in Combination With Paclitaxel (Taxol) on Prostate Cancer LNCaP Cells Cultured in Vitro or Grown as Xenograft Tumors in Immunodeficient Mice,” Clin Ca… [cited by applicant]
International Preliminary Report on Patentability for International patent application PCT/US2016/0611711, dated May 15, 2018. [cited by applicant]
International Search Report for International patent application PCT/US2016/0611711, dated May 26, 2017 (3 pages). [cited by applicant]
Collier et al., 2014 “Ingenol mebutate: a novel treatment for actinic keratosis,” Clin Pract 11(3):295-306. [cited by applicant]
Chen et al., “An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate,” JAMA Intern Med., 2019; 179(7):915-921. doi:10.1001/jamainternmed.2019.0583. [cited by applicant]
Kulkosky, et al., “Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART,” Blood, 2001, 98(10):3006-3015. [cited by applicant]